Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859
Phase 1, Randomized, Double-blind, Third-party Open Placebo-controlled, Dose Escalating Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of Single And Multiple Intravenous And Subcutaneous Doses Of Pf-06823859 In Healthy Subjects
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Connecticut
-
New Haven, Connecticut, United States, 06511
- Pfizer New Haven Clinical Research Unit
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy female subjects of non childbearing potential and male subjects who, at the time of screening, are between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical laboratory tests.
- Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).
Exclusion Criteria:
- History of active or latent tuberculosis (TB) regardless of treatment; positive Quantiferon - TB test.
- Subjects with a history of autoimmune disorders.
- Subjects with a history of or positive results for any of the following serological tests: Hepatitis B surface antigen (HBsAg), Hepatitis B core antibody (HBcAb), anti Hepatitis C antibody (HCVAb) or human immunodeficiency virus (HIV).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo injection SC/IV
Placebo for injection SC/IV
|
Comparison of Placebo to different doses of PF-06823859
Other Names:
|
|
ACTIVE_COMPARATOR: PF-06823859
Study Drug being used in the study
|
Comparison of different dosages of PF-06823859 to placebo
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants With Treatment Emergent Treatment-Related Adverse Events (AEs
Time Frame: Dosing through approximately Day 189
|
Safety
|
Dosing through approximately Day 189
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Apparent Clearance (CL) of PF-06823859
Time Frame: Pre dose to approximately Day 189
|
Pharmacokinetics
|
Pre dose to approximately Day 189
|
|
Area Under the Curve From Time Zero to Extrapolated Infinite Time [AUC (0 - ∞)] of PF-06823859
Time Frame: Pre dose to approximately Day 189
|
Pharmacokinetics
|
Pre dose to approximately Day 189
|
|
Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of PF-06823859
Time Frame: Pre dose to approximately Day 189
|
Pharmacokinetics
|
Pre dose to approximately Day 189
|
|
Number of Participants With Anti-Drug Antibody (ADA) to PF-06823859
Time Frame: Pre dose to approximately Day 189
|
Immunogenicity
|
Pre dose to approximately Day 189
|
|
Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-t)] of PF-06823859
Time Frame: Pre dose to approximately Day 189
|
Pharmacokinetics
|
Pre dose to approximately Day 189
|
|
Maximum Observed Plasma Concentration (Cmax) of PF-06823859
Time Frame: Pre dose to approximately Day 189
|
Pharmacokinetics
|
Pre dose to approximately Day 189
|
|
Plasma Decay Half-Life (t1/2)
Time Frame: Pre dose to approximately Day 189
|
Pharmacokinetics
|
Pre dose to approximately Day 189
|
|
Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-06823859 administered subcutaneously
Time Frame: Pre dose to approximately Day 189
|
Pharmacokinetics
|
Pre dose to approximately Day 189
|
|
Volume of Distribution at Steady State (Vss) of PF-06823859
Time Frame: Pre dose to approximately Day 189
|
Pharmacokinetics
|
Pre dose to approximately Day 189
|
|
AUCtau (dose normalized)
Time Frame: Pre dose to approximately Day 189
|
Pharmacokinetics
|
Pre dose to approximately Day 189
|
|
C av of PF-06823859
Time Frame: Pre dose to approximately Day 189
|
Pharmacokinetics
|
Pre dose to approximately Day 189
|
|
Mean residence of time for PF-06823859
Time Frame: Pre dose to approximately Day 189
|
Pharmacokinetics
|
Pre dose to approximately Day 189
|
|
Maximum Observed Plasma Concentration (Cmax) dose normalized of PF-06823859
Time Frame: Pre dose to approximately Day 189
|
Pharmacokinetics
|
Pre dose to approximately Day 189
|
|
bioavailability of PF-06823859 subcutaneous doses compared to intravenous doses of PF-06823859
Time Frame: Pre dose to approximately Day 189
|
Pharmacokinetics
|
Pre dose to approximately Day 189
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- C0251001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.